Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times

Bailly, Christian; Thuru, Xavier; Quesnel, Bruno

Type de document :

Compte-rendu et recension critique d'ouvrage

DOI :

10.1093/narcan/zcaa002

URL permanente :

http://hdl.handle.net/20.500.12210/108109

Titre :

Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times

Auteur(s) :

Bailly, Christian [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Thuru, Xavier [Auteur]

Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]
Quesnel, Bruno [Auteur]

Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 [JPArc]

Titre de la revue :

NAR Cancer

Pagination :

zcaa002

Éditeur :

Oxford University Press

Date de publication :

2020-03-01

Discipline(s) HAL :

Sciences du Vivant [q-bio]/Immunologie

Résumé en anglais : [en]

Monoclonal antibodies targeting programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not all patients equally benefit from immunotherapy. ...
Lire la suite >Monoclonal antibodies targeting programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoints have improved the treatments of cancers. However, not all patients equally benefit from immunotherapy. The use of cytotoxic drugs is practically inevitable to treat advanced cancers and metastases. The repertoire of cytotoxics includes 80 products that principally target nucleic acids or the microtubule network in rapidly proliferating tumor cells. Paradoxically, many of these compounds tend to become essential to promote the activity of immunotherapy and to offer a sustained therapeutic effect. We have analyzed each cytotoxic drug with respect to effect on expression and function of PD-(L)1. The major cytotoxic drugs—carboplatin, cisplatin, cytarabine, dacarbazine, docetaxel, doxorubicin, ecteinascidin, etoposide, fluorouracil, gemcitabine, irinotecan, oxaliplatin, paclitaxel and pemetrexed—all have the capacity to upregulate PD-L1 expression on cancer cells (via the generation of danger signals) and to promote antitumor immunogenicity, via activation of cytotoxic T lymphocytes, maturation of antigen-presenting cells, depletion of immunosuppressive regulatory T cells and/or expansion of myeloid-derived suppressor cells. The use of ‘immunocompatible’ cytotoxic drugs combined with anti-PD-(L)1 antibodies is a modern approach, not only for increasing the direct killing of cancer cells, but also as a strategy to minimize the activation of immunosuppressive and cancer cell prosurvival program responses.Lire moins >

Langue :

Anglais

Vulgarisation :

Non

Collections :

Date de dépôt :

2024-02-17T04:30:49Z

Fichiers

pdf
Accès libre
Accéder au document

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209987/pdf
Accès libre
Accéder au document

zcaa002.pdf
Accès libre
Accéder au document

document
Accès libre
Accéder au document

Combined cytotoxic chemotherapy and ... BibTeX CSV Excel RIS

Fichiers

Combined cytotoxic chemotherapy and ...

BibTeX

CSV

Excel

RIS